Biochemical Pharmacology, 158, 413-424. Elsevier Inc. Bobkov, V, Zarca, A M, van Hout, A, Arimont, M, Doijen, J, Bialkowska, M, Toffoli, E, Klarenbeek, A, vanderWoning, B, vander Vliet, H J, van Loy, T, de Haard, H, Schols, D, Heukers, R & Smit, M J 2018, ' Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions ', Biochemical Pharmacology, vol. 158, pp. 413-424 . https://doi.org/10.1016/j.bcp.2018.10.014 Biochemical Pharmacology Bobkov, V, Zarca, A M, Van Hout, A, Arimont, M, Doijen, J, Bialkowska, M, Toffoli, E, Klarenbeek, A, vanderWoning, B, vander Vliet, H J, Van Loy, T, de Haard, H, Schols, D, Heukers, R & Smit, M J 2018, ' Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions ', Biochemical Pharmacology, vol. 158, pp. 413-424 . https://doi.org/10.1016/j.bcp.2018.10.014